N/A N=60 The Drift-Reduction for Improved FFR Using Fiberoptic Technology (DRIFT) Study
Left Anterior Descending Coronary Artery Stenosis
Primary: Percentage of Recordings of Significant Drift in Pre and Post-PCI — 5.8 Percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=31 Pecto-intercostal Fascial Block (PIFB) for Postop Analgesia Following Sternotomy in Cardiac Surgery Patients
Analgesia · Sternotomy
Primary: Area Under the Curve (AUC) Pain Score - Based on Patient-reported Dynamic Numerical Rating Scale (NRS) Pain Scores — 6.39; 4.22 scores on a scale*hour
N/A N=99 Increasing Breast Cancer Screening in Chinese Immigrants
Screening Mammogram
Primary: Number of Participants That Scored Above 80% in the Feasibility and Acceptability Questionnaire — 99 Participants
N/A N=22 Bone Augmentation Techniques in Extraction Sockets
Tooth Loss
Primary: Changes in Hard Tissue Composition — 35.82; 31.76 mm
Phase 3 N=398 A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.3; 0.5 percentage points — p=< 0.0001
N/A N=181 Optimizing Function and Independence Through iHI-FIVES
Functional Impairment · Cognitive Impairment
Primary: Patient Number of Days Not at Home — 7.5; 13.0 number of days not at home — p=0.091
N/A N=312 PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics
Depression
Primary: Change in Edinburgh Postnatal Depression Scale Score (EPDS) — -4.3; -4.2 score on a scale
Phase 3 N=330 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
Atopic Dermatitis
Primary: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 10.8; 36.6; 56.5 percentage of participants…
Phase 1 N=60 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
Chikungunya Virus
Primary: Part A: Number of Participants With Any Solicited Adverse Events (AEs) (Local and Systemic Reactogenicity Events) — 11; 10; 11; 10 Participants
N/A N=161 Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors
Breast Cancer
Primary: Physical Activity — 145.83; 159.86; 172.94; 120.81 min/week — p=<.05
Phase 4 N=34 Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy
Cerebral Palsy · Hip Dysplasia · Pain, Postoperative
Primary: Opioid Consumption — 0.41; 1.87 mEQ/kg
N/A N=20 Long Term Clinical Investigation to Evaluate Clinical Performance, Safety and Patient Reported Outcomes of an Active Osseointegrated Steady-State Implant System
Hearing Loss
Primary: Number and Type of Reported Adverse Events — 44; 1; 16; 2 Number of events
N/A N=417 The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
COVID-19
Primary: Mechanical Ventilation — 21 Participants
Phase 1 N=60 Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Hookworm Disease · Hookworm Infection
Primary: Vaccine-Related Adverse Events — 8; 8; 8; 8 Participants
N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents